Protocol Ledger

NCT06730347 · Phase II · RECRUITING

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Interventional Phase II clinical trial protocol NCT06730347 sponsored by MacroGenics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-01 Enrollment: 80 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06730347
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)80 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06730347
Protocol FieldVerified Registry Value
NCT IdentifierNCT06730347
Consolidated Lead SponsorMacroGenics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment80 participants (ESTIMATED)
Registered Start Date2025-05-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI